149 related articles for article (PubMed ID: 31406250)
21. Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts.
Carlson BL; Grogan PT; Mladek AC; Schroeder MA; Kitange GJ; Decker PA; Giannini C; Wu W; Ballman KA; James CD; Sarkaria JN
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):212-9. PubMed ID: 19695438
[TBL] [Abstract][Full Text] [Related]
22. Effect of lomeguatrib-temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells.
Taspinar M; Ilgaz S; Ozdemir M; Ozkan T; Oztuna D; Canpinar H; Rey JA; Sunguroğlu A; Castresana JS; Ugur HC
Tumour Biol; 2013 Jun; 34(3):1935-47. PubMed ID: 23519841
[TBL] [Abstract][Full Text] [Related]
23. Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma.
Jiapaer S; Furuta T; Tanaka S; Kitabayashi T; Nakada M
Neurol Med Chir (Tokyo); 2018 Oct; 58(10):405-421. PubMed ID: 30249919
[TBL] [Abstract][Full Text] [Related]
24. Momelotinib sensitizes glioblastoma cells to temozolomide by enhancement of autophagy via JAK2/STAT3 inhibition.
Liu T; Li A; Xu Y; Xin Y
Oncol Rep; 2019 Mar; 41(3):1883-1892. PubMed ID: 30664175
[TBL] [Abstract][Full Text] [Related]
25. Transcriptional control of O
Happold C; Stojcheva N; Silginer M; Weiss T; Roth P; Reifenberger G; Weller M
J Neurochem; 2018 Mar; 144(6):780-790. PubMed ID: 29480969
[TBL] [Abstract][Full Text] [Related]
26. Combination of levetiracetam and IFN-α increased temozolomide efficacy in MGMT-positive glioma.
Ni XR; Guo CC; Yu YJ; Yu ZH; Cai HP; Wu WC; Ma JX; Chen FR; Wang J; Chen ZP
Cancer Chemother Pharmacol; 2020 Dec; 86(6):773-782. PubMed ID: 33074386
[TBL] [Abstract][Full Text] [Related]
27. Encapsulation of Temozolomide in a Calixarene Nanocapsule Improves Its Stability and Enhances Its Therapeutic Efficacy against Glioblastoma.
Renziehausen A; Tsiailanis AD; Perryman R; Stylos EK; Chatzigiannis C; O'Neill K; Crook T; Tzakos AG; Syed N
Mol Cancer Ther; 2019 Sep; 18(9):1497-1505. PubMed ID: 31213505
[TBL] [Abstract][Full Text] [Related]
28. Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas.
Yin AA; He YL; Etcheverry A; Liu YH; Aubry M; Barnholtz-Sloan J; Liu BL; Mosser J; Lu ZF; Zhang X
Clin Epigenetics; 2019 May; 11(1):76. PubMed ID: 31088577
[TBL] [Abstract][Full Text] [Related]
29. Temozolomide Is a Potential Therapeutic Tool for Patients With Metastatic Pheochromocytoma/Paraganglioma-Case Report and Review of the Literature.
Tong A; Li M; Cui Y; Ma X; Wang H; Li Y
Front Endocrinol (Lausanne); 2020; 11():61. PubMed ID: 32132978
[No Abstract] [Full Text] [Related]
30. Silencing SATB1 overcomes temozolomide resistance by downregulating MGMT expression and upregulating SLC22A18 expression in human glioblastoma cells.
Yang B; Ma YB; Chu SH
Cancer Gene Ther; 2018 Dec; 25(11-12):309-316. PubMed ID: 30140041
[TBL] [Abstract][Full Text] [Related]
31. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE
J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180
[TBL] [Abstract][Full Text] [Related]
32. IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma.
Guo G; Sun Y; Hong R; Xiong J; Lu Y; Liu Y; Lu J; Zhang Z; Guo C; Nan Y; Huang Q
Clin Transl Oncol; 2020 Aug; 22(8):1252-1262. PubMed ID: 31865606
[TBL] [Abstract][Full Text] [Related]
33. The Antiproliferative and Pro-apoptotic Effects of Methoxyamine on Pediatric Medulloblastoma Cell Lines Exposed to Ionizing Radiation and Chemotherapy.
Pezuk JA; Valera ET; Delsin LE; Scrideli CA; Tone LG; Brassesco MS
Cent Nerv Syst Agents Med Chem; 2015; 16(1):67-72. PubMed ID: 26553097
[TBL] [Abstract][Full Text] [Related]
34. A Key Role of DNA Damage-Inducible Transcript 4 (DDIT4) Connects Autophagy and GLUT3-Mediated Stemness To Desensitize Temozolomide Efficacy in Glioblastomas.
Ho KH; Chen PH; Chou CM; Shih CM; Lee YT; Cheng CH; Chen KC
Neurotherapeutics; 2020 Jul; 17(3):1212-1227. PubMed ID: 31916238
[TBL] [Abstract][Full Text] [Related]
35. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.
Siddiqui-Jain A; Drygin D; Streiner N; Chua P; Pierre F; O'Brien SE; Bliesath J; Omori M; Huser N; Ho C; Proffitt C; Schwaebe MK; Ryckman DM; Rice WG; Anderes K
Cancer Res; 2010 Dec; 70(24):10288-98. PubMed ID: 21159648
[TBL] [Abstract][Full Text] [Related]
36. Riluzole enhances the antitumor effects of temozolomide via suppression of MGMT expression in glioblastoma.
Yamada T; Tsuji S; Nakamura S; Egashira Y; Shimazawa M; Nakayama N; Yano H; Iwama T; Hara H
J Neurosurg; 2020 Mar; 134(3):701-710. PubMed ID: 32168477
[TBL] [Abstract][Full Text] [Related]
37. Sensitization of pancreatic tumor xenografts to carmustine and temozolomide by inactivation of their O6-Methylguanine-DNA methyltransferase with O6-benzylguanine or O6-benzyl-2'-deoxyguanosine.
Kokkinakis DM; Ahmed MM; Chendil D; Moschel RC; Pegg AE
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3801-7. PubMed ID: 14506174
[TBL] [Abstract][Full Text] [Related]
38. Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial.
Cefalo G; Massimino M; Ruggiero A; Barone G; Ridola V; Spreafico F; Potepan P; Abate ME; Mascarin M; Garrè ML; Perilongo G; Madon E; Colosimo C; Riccardi R
Neuro Oncol; 2014 May; 16(5):748-53. PubMed ID: 24482446
[TBL] [Abstract][Full Text] [Related]
39. O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells.
Hermisson M; Klumpp A; Wick W; Wischhusen J; Nagel G; Roos W; Kaina B; Weller M
J Neurochem; 2006 Feb; 96(3):766-76. PubMed ID: 16405512
[TBL] [Abstract][Full Text] [Related]
40. Casein Kinase II (CK2) as a Therapeutic Target for Hematological Malignancies.
Gowda C; Sachdev M; Muthusami S; Kapadia M; Petrovic-Dovat L; Hartman M; Ding Y; Song C; Payne JL; Tan BH; Dovat S
Curr Pharm Des; 2017; 23(1):95-107. PubMed ID: 27719640
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]